Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1977 results about "Gemella" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gemella is a genus of Gram-positive bacteria that thrive best at high partial pressure of CO₂.
Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Owner:FINCH THERAPEUTICS HLDG LLC
Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Owner:FINCH THERAPEUTICS HLDG LLC
Methods of combining metagenome and the metatranscriptome in multiplex profiles
The present invention describes changes in bacterial gastrointestinal, cutaneous and nasal microbiota associated various mammalian medical conditions. Described are diagnostic tests that arise from combining phylogenetic information about the families, genus, and species of the microbiome and their relative abundance with the metabolic information contained in the metatranscriptome to determine the presence and absence of a disease or medical condition. Provided are compositions of bacteria, co-cultures of bacteria and a carrier for use in treating the disclosed medical conditions. The described compositions restore or correct disease- or medical condition-related imbalances in the microbiome profile with culture-conditioned formulations in which the transcriptome activity of the administered organisms is optimized. Alternatively, formulations of metabolites that drive changes in the metatranscriptome native to the mammal that treat disease or a medical condition or restore health are taught.
Owner:ENSISHEIM PARTNERS
Tagged microorganisms and methods of tagging
The present invention provides methods for tagging and / or identifying microorganisms. In some preferred embodiments, the microorganisms are bacteria. In some particularly preferred embodiments, the bacteria are members of the genus Streptococcus, while in other embodiments, the bacteria are members of other genera. The present invention also provides microorganisms tagged using the methods set forth herein. In some preferred embodiments, the tagged microorganisms are bacteria. In some particularly preferred embodiments, the tagged bacteria are members of the genus Streptococcus, while in other embodiments, the tagged bacteria are members of other genera.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Method of treating gastrointestinal diseases associated with species of genus clostridium
The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.
Owner:UNITED STATES OF AMERICA
Bacillus sp. D747 strain, plant disease controlling agents and insect pest controlling agents using the same and control method using the agents
The present invention relates to a novel strain of Bacillus sp. D747 (deposited as FERM BP-8234) and methods for controlling plant diseases and insect pests, comprising administering cultures of Bacillus sp. D747 (including the viable bacteria) or viable bacteria isolated by culturing, on the plant parts such as roots, stems, leaves, seeds, and the like, or in the culture soil.
Owner:KUMIAI CHEM IND CO LTD
Tagged Microorganisms and Methods of Tagging
The present invention provides methods for tagging and / or identifying microorganisms. In some preferred embodiments, the microorganisms are bacteria. In some particularly preferred embodiments, the bacteria are members of the genus Streptococcus, while in other embodiments, the bacteria are members of other genera. The present invention also provides microorganisms tagged using the methods set forth herein. In some preferred embodiments, the tagged microorganisms are bacteria. In some particularly preferred embodiments, the tagged bacteria are members of the genus Streptococcus, while in other embodiments, the tagged bacteria are members of other genera.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Novel Ethanologenic Clostridium species, Clostridium coskatii
A novel clostridia bacterial species (Clostridium coskatii ATCC No. PTA-10522, “PS02”) is provided. Under anaerobic conditions C. coskatii can convert CO and / or H2 and / or CO2 to ethanol or acetate. Thus, this novel bacterium is capable of transforming waste gases (e.g. syngas and refinery wastes) into useful products.
Owner:SYNATA BIO INC
Solvent tolerant microorganisms
Pediococcus bacteria having enhanced tolerance to butanols have been isolated. The bacteria are useful for the fermentative production of butanol.
Owner:GEVO INC
Competitive and Effective Bacterial Strains
ActiveUS20120252672A1Improve availabilityImprove plant health of plantBiocidePlant growth regulatorsBacteroidesGrowth plant
According to the present invention new isolates of bacterial strains have been shown to possess unique properties. These bacterial strains are plant growth-promoting rhizobacterium (PGPR), posses an enhanced competitive advantage at colonizing leguminous plants, and enhance the overall performance of leguminous plant growth. Further still, the present invention discloses a novel method for screening and selecting bacterial strains having the aforementioned beneficial characteristics.
Owner:NOVOZYMES BIOLOGICALS
Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.
Owner:GANEDEN BIOTECH
Detection and typing of bacterial strains
Methods for the detection and typing of bacterial strains from food products and dietary supplements, environmental samples, in vivo / in vitro samples, and for studying the natural diversity of the species are disclosed. Potential applications also include product development and / or detection and differentiation of new bacterial strains.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Probe, probe set, probe-immobilized carrier, and genetic testing method
InactiveUS20080161192A1Quickly and precisely identifiedAccurate distinctionSugar derivativesMicrobiological testing/measurementBacteroidesNucleic Acid Probes
A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 87 to 89 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.
Owner:CANON KK
Media supplements and methods to culture human gastrointestinal anaerobic microorganisms
InactiveUS20140342438A1Enhance their axenic growthAntibacterial agentsBacteriaBacteroidesAnaerobic bacteria
A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of effluent from a chemostat vessel in which a target bacterial ecosystem has been cultured. Methods of using the supplement for culturing or isolating anaerobic microbial strains or communities, particularly anaerobic bacteria from the human gut, are also provided.
Owner:UNIVERSITY OF GUELPH
Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
ActiveUS20100074872A1Growth inhibitionFacilitate calorie uptakeBiocideMetabolism disorderBacteroidesDisease
The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.
Owner:NEW YORK UNIV
Attenuated Listeria spp. and methods for using the same
Attenuated Listeria bacteria are provided. The subject bacteria are characterized by having a mutation in a gene chosen from the lplA gene and the hly gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.
Owner:RGT UNIV OF CALIFORNIA
Bioluminescent biosensor device
InactiveUS6544729B2Less stressRapid and sensitive detectionAnalysis using chemical indicatorsSugar derivativesBacteroidesBacterial strain
Disclosed are methods and devices for detection of bacteria based on recognition and infection of one or more selected strains of bacteria with bacteriophage genetically modified to cause production of an inducer molecule in the bacterium following phage infection. The inducer molecule is released from the infected bacterium and is detected by genetically modified bacterial bioreporter cells designed to emit bioluminescence upon stimulation by the inducer. Autoamplification of the bioluminescent signal permits detection of low levels of bacteria without sample enrichment. Also disclosed are methods of detection for select bacteria, and kits for detection of select bacteria based on the described technology.
Owner:UNIVERSITY OF TENNESSEE +1
Pharmaceutical Composition for Protection from Allergies and Inflammatory Disorders
The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and / or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.
Owner:FORSCHUNGSZENTRUM BORSTEL +1
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
InactiveUS20060165716A1InhibitionEasy to eliminateAntibacterial agentsBacterial antigen ingredientsBacteroidesVirulent characteristics
The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Method for increasing the tenderness of a meat product
A method for preserving a food product, such as meat, including the steps of inoculating meat with an effective amount of euhygienic non-pathogenic, non-spoilage bacteria in order to competitively inhibit the growth of undesired pathogenic and spoilage bacteria. Edible films that incorporate and / or cover euhygenic bacteria on the food product are used to ensure competitive inhibition of undesired spoilage and pathogenic bacteria.
Owner:SWIFT BEEF +1
Sushi peptide multimer
Endotoxin, also known as lipopolysaccharides (LPS), is the major mediator of septic shock due to Gram-negative bacterial infection. Chemically synthesized S3 peptide, derived from Sushi3 domain of Factor C, which is the endotoxin-sensitive serine protease of the limulus coagulation cascade, binds and neutralizes LPS activity. Fluorescent tagged-S3 is shown to detect LPS-containing bacteria. For large-scale production of S3 and to mimic other pathogen-recognizing molecules, tandem multimers of the S3 gene were constructed and expressed in E. coli. Tetramer of S3 for example is shown to display an enhanced inhibitory effect on LPS-induced activities. An affinity matrix based on tetramer of S3 is also shown to be particularly efficient at removing LPS.
Owner:NAT UNIV OF SINGAPORE
Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
InactiveCN104160014APromote proliferationPromote accumulationBacteriaAntipyreticBacteroidesRegulatory T cell
Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
Owner:THE UNIV OF TOKYO +1
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
InactiveUS6939543B2Enhance phagocytosis and killing of the bacteriaIncrease infectionAntibacterial agentsHybrid immunoglobulinsBacteroidesBinding site
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and / or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC +1
Strain of biocontrol Streptomyces and application thereof
The invention discloses a strain of Streptomyces and application thereof. The biocontrol Streptomyces is blastmycin Streptomyces and its strain number is JZB130180, which is registered in the general microbiological center of China Committee for Culture Collection of Microorganisms with CGMCC No. 13270. The strain had significant antagonistic effect on 14 kinds of plant pathogenic fungi and 6 kinds of plant pathogenic bacteria in agricultural production, and has wide antimicrobial spectrum. The strain produces chitinase, cellulase, protease and selenium, and has the basic characteristics of biocontrol bacteria. The fermentation broth of this strain has strong control effect on tomato gray mold and peach brown rot, and has significant promotion action on the tomato plants, which indicated that the strain had a broad application prospect in the field of biological control of plant diseases.
Owner:BEIJING ACADEMY OF AGRICULTURE & FORESTRY SCIENCES
Gna1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
ActiveUS20080248065A1Broad protectionDecrease of emergenceAntibacterial agentsBacterial antigen ingredientsBacteroidesDisease
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN
Antibacterial composition and method of production
An electrolysis method is described for generating an aqueous solution of copper citrate that has bacteriocidal activity against methicillin resistant Staphylococcus aureus (MRSA) bacteria. Gram positive bacteria are known to be relatively more sensitive to the bacteriocidal activities of copper ions than are Gram negative bacteria. Situations exist in which a disinfectant that is relatively more toxic for Gram positive bacteria will be advantageous over a more broadly active disinfectant, such as that provided by most other disinfectants. In particular, a disinfectant that is relatively selective for Gram positive bacteria could help preserve various non-pathogenic Gram negative microbial populations. The residual Gram negative bacteria can potentially compete with, and thereby lessen the chances of the reintroduction of pathogenic Gram positive bacteria, such as MRSA, Streptococcus, Clostridium difficile and Listeria monocytogenes.
Owner:MI HOPE
Recombinant bacteriophage and methods for their use
Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.
Owner:PYLUM BIOSCI INC
Novel lysin protein having broad antibacterial activity specific to bacteria
ActiveUS20100172918A1Strong specificityLow toxicityAntibacterial agentsBacterial antigen ingredientsBacteroidesAntibacterial activity
The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.
Owner:INTRON BIOTECHNOLOGY INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com